BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35472492)

  • 1. Sorafenib-induced liver failure in a hepatocellular carcinoma patient: Letter to the editor.
    Chou TP; Hu JT; Hung CS; Chen HY
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101931. PubMed ID: 35472492
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
    J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.
    Arora SP; Ananth S; Ketchum N; Gelfond J; Michalek J; Mahalingam D
    J Geriatr Oncol; 2020 Sep; 11(7):1157-1160. PubMed ID: 32273248
    [No Abstract]   [Full Text] [Related]  

  • 4. Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib.
    Madabhavi I; Patel A; Anand A; Choudhary M; Revannasiddaiah S
    J Cancer Res Ther; 2015; 11(4):1029. PubMed ID: 26881607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 6. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
    Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
    Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
    Francini E; Bianco V
    Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
    [No Abstract]   [Full Text] [Related]  

  • 8. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
    Xu L; Wang B; Ding W
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
    Mancuso A; Zavaglia C; Bai F; Puoti M; Belli LS
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1414-6. PubMed ID: 24206381
    [No Abstract]   [Full Text] [Related]  

  • 10. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    Park H; Han SH; Kang H; Park K
    Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
    [No Abstract]   [Full Text] [Related]  

  • 11. Painful Rashes on the Palms and Soles.
    Bhullar M; Bhullar A; Arachchi NJ
    Ann Acad Med Singap; 2016 Oct; 45(10):479-480. PubMed ID: 27832225
    [No Abstract]   [Full Text] [Related]  

  • 12. Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
    Chou JW; Cheng KS; Huang CW
    Intern Med; 2016; 55(6):623-7. PubMed ID: 26984079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S; de Gramont A; Raymond E
    Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
    [No Abstract]   [Full Text] [Related]  

  • 14. Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
    Takahashi Y; Fukunishi S; Nishikawa T; Nouda S; Sasaki Y; Sanomura M; Umegaki E; Higuchi K
    Endoscopy; 2013; 45 Suppl 2 UCTN():E179-80. PubMed ID: 23801291
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
    Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
    Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
    [No Abstract]   [Full Text] [Related]  

  • 16. Grade III hand-foot skin reaction induced by sorafenib.
    Chiriac A; Coros MF; Podoleanu C; Stolnicu S
    An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
    [No Abstract]   [Full Text] [Related]  

  • 17. Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
    Coppola R; Zanframundo S; Rinati MV; Carbotti M; Graziano A; Galati G; De Florio L; Panasiti V
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1028-9. PubMed ID: 24628665
    [No Abstract]   [Full Text] [Related]  

  • 18. Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
    Tajiri K; Nakajima T; Kawai K; Minemura M; Sugiyama T
    Intern Med; 2015; 54(6):597-600. PubMed ID: 25786448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of intermediate-stage hepatocellular carcinoma.
    Finn RS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
    [No Abstract]   [Full Text] [Related]  

  • 20. Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.
    Adachi T; Hiraoka A; Okazaki H; Nagamatsu K; Izumoto H; Yoshino T; Tsuruta M; Aibiki T; Okudaira T; Yamago H; Iwasaki R; Suga Y; Mori K; Miyata H; Tsubouchi E; Ninomiya T; Michitaka K
    Clin J Gastroenterol; 2020 Oct; 13(5):891-895. PubMed ID: 32468502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.